Drug Profile
Posdinemab - Johnson & Johnson Innovative Medicine
Alternative Names: Anti-phospho-tau mAb; JNJ-3657; JNJ-63733657Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Janssen Research & Development
- Class Antibodies; Antidementias; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
Most Recent Events
- 16 Jul 2023 Pharmacodynamics data from a phase II trial in Alzheimer's disease presented at the Alzheimer's Association International Conference (AAIC-2023)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Alzheimer's-disease in Germany (IV)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Alzheimer's-disease in Netherlands (IV)